95 related articles for article (PubMed ID: 17141949)
1. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.
Mueller L; Goumas FA; Himpel S; Brilloff S; Rogiers X; Broering DC
Cancer Lett; 2007 Jun; 250(2):329-38. PubMed ID: 17141949
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
4. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.
Sandler C; Joutsiniemi S; Lindstedt KA; Juutilainen T; Kovanen PT; Eklund KK
Biochem Biophys Res Commun; 2006 Aug; 347(1):31-5. PubMed ID: 16806061
[TBL] [Abstract][Full Text] [Related]
6. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.
Lozano E; Segarra M; García-Martínez A; Hernández-Rodríguez J; Cid MC
Ann Rheum Dis; 2008 Nov; 67(11):1581-8. PubMed ID: 17584806
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
10. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
12. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
13. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.
Kaminski A; Hahne JC; Haddouti el-M; Florin A; Wellmann A; Wernert N
Int J Mol Med; 2006 Nov; 18(5):941-50. PubMed ID: 17016625
[TBL] [Abstract][Full Text] [Related]
14. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Rocha A; Azevedo I; Soares R
J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
[TBL] [Abstract][Full Text] [Related]
15. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells.
Rocha A; Azevedo I; Soares R
Angiogenesis; 2007; 10(4):279-86. PubMed ID: 17876712
[TBL] [Abstract][Full Text] [Related]
17. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.
Yamanashi T; Nakanishi Y; Fujii G; Akishima-Fukasawa Y; Moriya Y; Kanai Y; Watanabe M; Hirohashi S
Oncology; 2009; 77(1):53-62. PubMed ID: 19556810
[TBL] [Abstract][Full Text] [Related]
18. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
Prunotto M; Bosco M; Daniele L; Macri' L; Bonello L; Schirosi L; Rossi G; Filosso P; Mussa B; Sapino A
Lung Cancer; 2009 May; 64(2):244-6. PubMed ID: 19041155
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.
Takayama Y; Kokuryo T; Yokoyama Y; Nagino M; Nimura Y; Senga T; Hamaguchi M
Cancer Lett; 2008 Jun; 264(2):241-9. PubMed ID: 18346844
[TBL] [Abstract][Full Text] [Related]
20. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
